NASDAQ:ALT
Altimmune, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
altimmune.comipo date
May 26, 2017
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcel...Show More
Earnings
Earnings Release in 12 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus